IntalTarget Therapeutics

IntalTarget Therapeutics is a biotechnology company specializing in the development of intracellular biologics to address "undruggable" targets. The company utilizes its proprietary IntalTarget platform to enable large molecules, such as antibodies and proteins, to cross the cell membrane and reach the cytoplasm and nucleus. This approach combines the high specificity of biologics with the reach of small molecules, focusing on high-value targets like KRAS and MYC. Headquartered in Suzhou, China, the company is advancing a pipeline of innovative therapies for oncology and other therapeutic areas with significant unmet needs. By bridging the gap between traditional modalities, IntalTarget aims to expand the therapeutic landscape for precision medicine.